Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Tumor”

9,457 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 9,457 results

Testing effectiveness (Phase 2)WithdrawnNCT05170789
What this trial is testing

Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma

Who this might be right for
Relapsed Multiple MyelomaRefractory Multiple Myeloma
Tulane University School of Medicine
Testing effectiveness (Phase 2)Ended earlyNCT01023880
What this trial is testing

Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy

Who this might be right for
Multiple Myeloma
Cephalon 62
Early research (Phase 1)Not Yet RecruitingNCT07113496
What this trial is testing

RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies

Who this might be right for
Relapsed or Refractory B-cell Hematologic MalignanciesB-cell Acute Lymphoblastic Leukemia (B-ALL)Multiple Myeloma (MM)+3 more
The First Affiliated Hospital with Nanjing Medical University 27
Early research (Phase 1)Looking for participantsNCT02203903
What this trial is testing

Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies

Who this might be right for
Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS
Catherine Bollard 50
Testing effectiveness (Phase 2)UnknownNCT00003327
What this trial is testing

Paclitaxel in Treating Patients With Recurrent or Refractory Head and Neck Cancer

Who this might be right for
Head and Neck Cancer
Theradex 60
Testing effectiveness (Phase 2)UnknownNCT04296786
What this trial is testing

Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study

Who this might be right for
Cutaneous T-cell Lymphoma
Peking Union Medical College Hospital 52
Testing effectiveness (Phase 2)WithdrawnNCT00005969
What this trial is testing

Liposomal Tretinoin in Treating Patients With Recurrent or Refractory Hodgkin's Disease

Who this might be right for
Lymphoma
M.D. Anderson Cancer Center
Early research (Phase 1)Looking for participantsNCT07007117
What this trial is testing

PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma

Who this might be right for
Refractory NeuroblastomaRelapsed NeuroblastomaHigh-Risk Neuroblastoma
Stephan Grupp MD PhD 38
Testing effectiveness (Phase 2)Study completedNCT02558868
What this trial is testing

Second-Line Oxaliplatin and Irinotecan Versus Irinotecan Alone for Gemcitabine and S-1 Refractory Pancreatic Cancer

Who this might be right for
Pancreatic Neoplasms
Zhejiang University 80
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07419880
What this trial is testing

Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer

Who this might be right for
Triple -Negative Breast Cancer
Fudan University 46
Testing effectiveness (Phase 2)UnknownNCT00003827
What this trial is testing

Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome

Who this might be right for
LeukemiaMyelodysplastic Syndromes
ALZA 25
Early research (Phase 1)Ended earlyNCT05712278
What this trial is testing

Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukaemia
Sanofi 7
Very early researchLooking for participantsNCT06092047
What this trial is testing

UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.

Who this might be right for
CD19-positive Relapsed or Refractory B-cell Malignancies
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 10
Testing effectiveness (Phase 2)Study completedNCT00048555
What this trial is testing

Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkin's Lymphoma
Biogen 90
Early research (Phase 1)Study completedNCT00720148
What this trial is testing

A Phase I Trial of Bortezomib and Sunitinib

Who this might be right for
Solid Tumors
Emory University 30
Early research (Phase 1)Study completedNCT01017185
What this trial is testing

Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions

Who this might be right for
Refractory Head and Neck CancerSquamous Cell Carcinoma, SkinCarcinoma of the Breast+1 more
Takara Bio Inc. 28
Early research (Phase 1)WithdrawnNCT03605589
What this trial is testing

Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma

Who this might be right for
Leukemia, B-cellLymphoma, B-Cell
Children's Hospital Medical Center, Cincinnati
Testing effectiveness (Phase 2)Looking for participantsNCT07341191
What this trial is testing

Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy

Who this might be right for
Mantle Cell Lymphoma
Canadian Cancer Trials Group 40
Early research (Phase 1)UnknownNCT04861480
What this trial is testing

Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Chongqing Precision Biotech Co., Ltd 18
Testing effectiveness (Phase 2)Study completedNCT03686488
What this trial is testing

TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaGastric Cancer
H. Lee Moffitt Cancer Center and Research Institute 23
Load More Results